Demethoxycurcumin suppresses migration and invasion of MDA-MB-231 human breast cancer cell line

Yodkeeree, Supachai; Ampasavate, Chadarat; Sung, Bokyung; Aggarwal, Bharat B.; Limtrakul, Pornngarm

doi:10.1016/j.ejphar.2009.09.052

Cited by 106 publications

(71 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[27] Licorice Root extract (Glycyrrhiza uralensis) has been reported for inhibition of breast cancer cell (MCF-7) proliferation by modulating the pathways of Bcl-2/Bax apoptosis G1 cell cycle [28,29] Tecomella undulata bark extract shows antiproliferative activity on K562 cells. [30] In our study, we have evaluated the anticancer activity of herbo-mineral formulation CYTOCRUEL on breast cancer cells (MDA-MB-231) and lung cancer cells (A549).…”

Section: Discussionmentioning

confidence: 99%

Anticancer Activity of Herbo-Mineral Formulation in Vitro: A Preliminary Study

Mehta¹

2017

WJPPS

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Anticancer Activity of Herbo-Mineral Formulation in Vitro: A Preliminary Study

Mehta¹

2017

WJPPS

View full text Add to dashboard Cite

show abstract

“…It inhibits proliferation of breast cancer cell lines by down regulation of cell cycle regulators such as cyclin D and NF-kB, and inhibits metastasis of the triple negative breast cancer cell line MDA-MB-231 [1,2]. It has also been shown to induce apoptosis of breast cancer cells by inhibiting survivin, the survival protein and modulate BRCA1 protein [3].…”

Section: Phytochemicals That Have Been Shown To Be Active Against Brementioning

confidence: 99%

Complementary/Alternative Medicine Strategies for Prevention and or Cure of Breast Cancer: A Review

Raj¹,

Ireland²,

Ouhtit³

et al. 2015

Women Heal Int

View full text Add to dashboard Cite

“…Yodkeeree et al [62] have reported that demethoxycurcumin (DMC, 59) inhibits adhesion, migration and invasion of MDA-MB-231 human breast cancer cells. MDA-MB-231 cells treated with DMC had decreased levels of extracellular matrix (ECM) degradationassociated proteins including matrix metalloproteinase-9 (MMP-9), membrane type-1 matrix metalloproteinase (MT1-MMP), urokinase plasminogen activator (uPA) and uPA receptor (uPAR), while the level of uPA inhibitor (PAI-1) was up-regulated.…”

Section: Modifications Of Aryl Sidementioning

confidence: 99%

“…Similarly data on their in vivo activities in most cases is lacking. [64] have investigated the role of carbonyl and hydroxyl groups of Curcumin in PKC binding by synthesizing pyrazole (61)(62) and isoxazole (63-65) derivatives and studying their interaction with protein kinase-C (PKC-), especially with the activator-binding second cysteine-rich C1B sub-domain. All synthesized derivatives showed higher binding with the PKC--C1B compared with PKC--C1B and PKC--C1B.…”

Section: Modifications Of Aryl Sidementioning

confidence: 99%

Perspectives on New Synthetic Curcumin Analogs and their Potential Anticancer Properties

Vyas¹,

Dandawate²,

Padhyé³

et al. 2013

Current Pharmaceutical Design

View full text Add to dashboard Cite

Curcumin is the active component of dried rhizome of Curcuma longa, a perennial herb belonging to ginger family, cultivated extensively in south and southeastern tropical Asia. It is widely consumed in the Indian subcontinent, south Asia and Japan in traditional food recipes. Extensive research over last few decades has shown that curcumin is a potent anti-inflammatory agent with powerful therapeutic potential against a variety of cancers. It suppresses proliferation and metastasis of human tumors through regulation of various transcription factors, growth factors, inflammatory cytokines, protein kinases and other enzymes. It induces apoptotic cell death and also inhibits proliferation of cancer cells by cell cycle arrest. Pharmacokinetic data has shown that curcumin undergoes rapid metabolism leading to glucuronidation and sulfation in the liver and excretion in the feces, which accounts for its poor systemic bioavailability. The compound has, therefore, been formulated and administered using different drug delivery systems such as liposomes, micelles, polysaccharides, phospholipid complexes and nanoparticles that can overcome the limitation of bioavailability to some extent. Attempts to avoid rapid metabolism of curcumin until now have been met with limited success. This has prompted researchers to look for new synthetic curcumin analogs in order to overcome the drawbacks of limited bioavailability and rapid metabolism, and gain efficacy with reduced toxicity. In this review we provide a summarized account of novel synthetic curcumin formulations and analogs, and the recent progress in the field of cancer prevention and treatment.

show abstract

Demethoxycurcumin suppresses migration and invasion of MDA-MB-231 human breast cancer cell line

Cited by 106 publications

References 41 publications

Anticancer Activity of Herbo-Mineral Formulation in Vitro: A Preliminary Study

Anticancer Activity of Herbo-Mineral Formulation in Vitro: A Preliminary Study

Complementary/Alternative Medicine Strategies for Prevention and or Cure of Breast Cancer: A Review

Perspectives on New Synthetic Curcumin Analogs and their Potential Anticancer Properties

Contact Info

Product

Resources

About